The Medicines Co. filed a registration statement to offer up to 4 million shares of stock to fund its pipeline and, most notably, Angiomax. The company said in its prospectus it expected to receive, assuming an offering price of $18.94 per share, about $70.9 million after deducting underwriting discounts, commissions and other expenses. (BioWorld Today)

The Medicines Co. filed a registration statement to offer up to 4 million shares of stock to fund its pipeline and, most notably, Angiomax. The company said in its prospectus it expected to receive, assuming an offering price of $18.94 per share, about $70.9 million after deducting underwriting discounts, commissions and other expenses. (BioWorld Today)